X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aurobindo Pharma Fact Sheet, Aurobindo Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aurobindo Pharma Fact Sheet   (AUBD)

Here is the latest financial fact sheet of Aurobindo Pharma. For more details, see the Aurobindo Pharma quarterly results and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

AUROBINDO PHARMA Price History

Price Rs 749.7
Mkt Cap Rs m 438,701
Vol '000 76.1
P/E X 20.0
P/CF X 14.7
EPS (TTM) Rs 37.4
% ch % 1.3
No. of shares m 585.17
% ch week % -5.9
% ch 1-mth % -6.1
% ch 12-mth % 10.7
52 week H/L Rs 830.0/527.1
(As on Dec 13, 2018 12:13:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AUROBINDO PHARMA Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
AUROBINDO PHARMA EQUITY SHARE DATA
High Rs5451,2801,541895809 
Low Rs139509582622504 
Sales per share (Unadj.) Rs277.9415.1235.8254.6281.1 
Earnings per share (Unadj.) Rs40.254.034.639.341.4 
Diluted earnings per shareRs20.026.934.639.341.4 
Cash flow per share (Unadj.) Rs51.065.441.346.650.9 
Dividends per share (Unadj.) Rs3.004.502.502.502.50 
Adj. dividends per shareRs1.492.252.502.502.50 
Dividend yield (eoy) %0.90.50.20.30.4 
Book value per share (Unadj.) Rs128.7184.5124.5160.0199.4 
Adj. book value per shareRs64.192.0124.5160.2199.6 
Shares outstanding (eoy) m291.46291.98585.17585.88585.88 
Bonus/Rights/Conversions  --PREFESOP- 
Price / Sales ratio x1.22.24.53.02.3 
Avg P/E ratio x8.516.630.719.315.9 
P/CF ratio (eoy) x6.713.725.716.312.9 
Price / Book Value ratio x2.74.88.54.73.3 
Dividend payout %7.58.37.26.46.0 
Avg Mkt Cap Rs m99,577261,147621,041444,390384,630 
No. of employees `0009.511.613.314.017.3 
Total wages/salary Rs m8,02413,02315,42617,67821,308 
Avg. sales/employee Rs Th8,526.110,469.510,384.310,667.89,500.7 
Avg. wages/employee Rs Th844.71,124.91,160.91,264.31,229.4 
Avg. net profit/employee Rs Th1,234.61,361.11,522.91,645.81,397.9 
AUROBINDO PHARMA INCOME DATA
Net Sales Rs m80,998121,205137,986149,157164,666 
Other income Rs m2169672,0381,1591,020 
Total revenues Rs m81,214122,172140,024150,316165,686 
Gross profit Rs m21,33725,63631,88234,34337,718 
Depreciation Rs m3,1253,3263,9244,2765,580 
Interest Rs m3,1021,5992,568667777 
Profit before tax Rs m15,32521,67927,42930,55832,380 
Minority Interest Rs m3845155031 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m3,6355,9667,2077,5978,183 
Profit after tax Rs m11,72915,75820,23623,01224,229 
Gross profit margin %26.321.223.123.022.9 
Effective tax rate %23.727.526.324.925.3 
Net profit margin %14.513.014.715.414.7 
AUROBINDO PHARMA BALANCE SHEET DATA
Current assets Rs m56,31283,794102,94492,062121,878 
Current liabilities Rs m42,20060,81478,40266,05686,806 
Net working cap to sales %17.419.017.817.421.3 
Current ratio x1.31.41.31.41.4 
Inventory Days Days107108107106130 
Debtors Days Days1191071226868 
Net fixed assets Rs m27,36639,21850,27862,91981,037 
Share capital Rs m292292585586586 
"Free" reserves Rs m35,80253,56572,28893,133116,218 
Net worth Rs m37,50253,85772,87393,719116,804 
Long term debt Rs m12,79413,1117,4281,8144,512 
Total assets Rs m94,898128,124159,202162,494211,052 
Interest coverage x5.914.611.746.842.7 
Debt to equity ratio x0.30.20.100 
Sales to assets ratio x0.90.90.90.90.8 
Return on assets %15.613.514.314.611.8 
Return on equity %31.329.327.824.620.7 
Return on capital %36.734.837.432.727.4 
Exports to sales %65.851.651.400 
Imports to sales %26.719.219.000 
Exports (fob) Rs m53,26962,51470,92700 
Imports (cif) Rs m21,60723,27226,19300 
Fx inflow Rs m53,42062,61371,01575,83880,727 
Fx outflow Rs m23,25125,32928,79930,22434,700 
Net fx Rs m30,16937,28442,21645,61346,027 
AUROBINDO PHARMA CASH FLOW
From Operations Rs m 6,463 12,368 14,198 32,786 19,548 
From Investments Rs m -8,187 -13,980 -14,452 -17,870 -19,570 
From Financial Activity Rs m 1,176 932 3,654 -19,153 8,642 
Net Cashflow Rs m -548 -680 3,397 -4,239 8,922 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 54.1%
Foreign collaborators 0.0%
Indian inst/Mut Fund 8.0%
FIIs 27.7%
ADR/GDR 0.0%
Free float 10.2%
Shareholders 69,601
Pledged promoter(s) holding 8.6%
 

Company Information

REGD OFF Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038
E-MAIL cs@aurobindo.com WEB www.aurobindo.com
TELEPHONE (040) 6672 5333 FAX (040) 2374 1080
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR S. R. Batliboi & Assoc.
CHM: K. Ragunathan COMP SEC: A. Mohan Rami Reddy YEAR OF INC: 1986 BSE CODE: 524804 FV (Rs): 1 DIV YIELD (%): 0.3

Read: AUROBINDO PHARMA 2017-18 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   UNICHEM LAB  STRIDES PHARMA SCIENCE  NATCO PHARMA  AJANTA PHARMA  SUN PHARMA  

Compare AUROBINDO PHARMA With:   UNICHEM LAB  STRIDES PHARMA SCIENCE  NATCO PHARMA  AJANTA PHARMA  SUN PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Strong; PSU & Realty Stocks Lead(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 1.3%.

Views on news

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Oct 3, 2018 | Updated on Oct 3, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - UNICHEM LAB COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS